This page in English

Ann-Charlotte Dreifaldt

Tjänstetitel: Universitetslektor, adjungerad Organisation: Institutionen för medicinska vetenskaper

E-post:

Telefon: 019 301468

Rum: C2108

Publikationer

Artiklar i tidskrifter |  Doktorsavhandlingar, sammanläggningar |  Manuskript | 

Artiklar i tidskrifter

Hatschek, T. , Foukakis, T. , Bjöhle, J. , Lekberg, T. , Fredholm, H. , Elinder, E. , Bosch, A. , Pekar, G. & et al. (2021). Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer A Phase 2 Randomized Clinical Trial. JAMA Oncology.
Hatschek, T. , Andersson, A. , Bjöhle, J. , Bosch, A. , Carlsson, L. , Dreifaldt, A. C. , Einbeigi, Z. , Elinder, E. & et al. (2020). PREDIX HER2 trial: Event-free survival and pathologic complete response in clinical subgroups and stromal TILs levels. Annals of Oncology, 31 (Suppl. 2), S49-S49.
Bergh, J. C. S. , Andersson, A. , Bjohle, J. , Bosch, A. , Carlsson, L. , Dreifaldt, A. C. , Einbeigi, Z. , Fredholm, H. & et al. (2019). Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard?. Journal of Clinical Oncology, 37 (15).
Brandberg, Y. , Andersson, A. , Bjohle, J. , Bosch, A. , Carlsson, L. , Dreifaldt, A. C. , Einbeigi, Z. , Fredholm, H. & et al. (2019). Health-related quality of life in the Swedish PREDIX HER2 trial, evaluating docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer.. Journal of Clinical Oncology, 37 (15).
Karlsson, J. , Dreifaldt, A. , Bohr Mordhorst, L. & Sorbe, B. (2017). Differences in outcome for cervical cancer patients treated with or without brachytherapy. Brachytherapy, 16 (1), 133-140.
Dreifaldt, A. C. , Carlberg, M. & Hardell, L. (2004). Increasing incidence rates of childhood malignant diseases in Sweden during the period 1960–1998. European Journal of Cancer, 40 (9), 1351-1360.
Hardell, L. & Dreifaldt, A. C. (2001). Breast-feeding duration and the risk of malignant diseases in childhood in Sweden. European Journal of Clinical Nutrition, 55 (3), 179-185.

Doktorsavhandlingar, sammanläggningar

Dreifaldt, A. C. (2006). Epidemiological aspects on malignant diseases in childhood. (Doctoral dissertation). (Sammanläggning) Örebro: Örebro universitetsbibliotek.

Manuskript